{
    "nctId": "NCT00955890",
    "briefTitle": "Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer",
    "officialTitle": "Randomized Phase II Trial Of Interventional Therapy Investigate Cardiac Protection of Dexrazoxane In Women With Breast Cancer Having Experienced Grade 1 Cardiotoxicity During Prior Anthracycline-based Chemotherapy.",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Occurence of cardiac toxicity in patients with breast cancer receiving anthracycline chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\nDISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary infiltrating adenocarcinoma of the breast\n\n  * Confirmed by core needle biopsy or incisional biopsy or surgery\n  * Experienced grade 1 cardiac toxicity during prior anthracycline-based chemotherapy\n  * At least 2 cycles same anthracycline based chemotherapy are needed\n\nExclusion Criteria:\n\n* Accumulated dose of EPI \u22651000mg/m2,ADM\u2265550mg/m2\n* With the following risk factors: Uncontrolled or severe cardiovascular disease (e.g., myocardial infarction within the past 6 months, congestive heart failure treated with medications, or uncontrolled hypertension); Prior or Concurrent radiation to heart\n* Pregnant or nursing\n* Other currently active malignancy except nonmelanoma skin cancer\n* Uncontrolled or severe bleeding,diarrhea,intestinal obstruction\n* Grade 2 or more Cardiac Toxicity (CTC AE3.0)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}